A randomized controlled trial for the effect of Modified Shenling Baizhu Powder on delaying the illness progress of COPD stable phase patients (GOLD 1-2 stages).
- Conditions
- Chronic Obstructive Pulmonary Disease
- Registration Number
- ITMCTR2000003887
- Lead Sponsor
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients with a clinical diagnosis of stable COPD (GOLD stage 1-2); consistent with TCM lung qi deficiency syndrome;
2. No history of respiratory tract infection or acute exacerbation in the 4 weeks prior to randomization;
3. Those who are able to successfully perform pulmonary function measurements;
4. Patients are informed and sign written consent form.
1. Patients with chronic lung diseases in which intervention or treatment is required, such as interstitial lung diseasebronchial asthma, active tuberculosis, or bronchiectasis;
2. Patients with a combination of severe primary diseases, such as cardiovascular and cerebrovascular diseases, liver and kidney diseases, hematopoietic system diseases, endocrine diseases, severe mental disorders, malignant tumors;
3. Patients have evidence of alcohol or drug abuse, known or suspected allergy to the study drug or some of its components, and currently uses oral corticosteroids regularly;
4. Women who are breast-feeding, pregnant or expecting a child;
5. Patients who have been involved in any other clinical study in the past 6 months;
6. Patients unable to successfully use a DPI or perform pulmonary function measurements.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method lung function;
- Secondary Outcome Measures
Name Time Method St George's Respiratory Questionnaire;COPD acute exacerbations;COPD assessment test;modified British medical research council;